Provided herein are methods for identifying a cancer patient at risk for resistance to an HDAC inhibitor therapy, comprising obtaining a tumor sample from the cancer patient detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample quantifying a level of the TSPYL5 expression in the sample, wherein a high level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, correlates with resistance to the HDAC inhibitor therapy and applying the correlation to identify the cancer patient at risk for resistance to the HDAC inhibitor therapy. Also provided is a method for identifying a cancer patient with an increased likelihood of a positive clinical response to an HDAC inhibitor therapy comprising obtaining a tumor sample from the cancer patient detecting the presence of Testis-specific Y-encoded-like protein 5 (TSPYL5) expression in said sample quantifying a level of said TSPYL5 expression in said sample, wherein a low level of the TSPYL5 expression, relative to a defined expression threshold of the TSPYL5, identifies said cancer patient with an increased likelihood of a positive clinical response to said HDAC inhibitor therapy. Related methods and compositions are also provided.本發明提供鑑別對HDAC抑制劑療法有產生抗性之風險之癌症患者的方法,其包含自該癌症患者獲得腫瘤樣品;偵測該樣品中睾丸特異性Y編碼樣蛋白質5(TSPYL5)表現之存在;定量該樣品中該TSPYL5之表現量,其中相對於該TSPYL5之既定表現臨限值,該TSPYL5之表現量高與對該HDAC抑制劑療法之抗性有關;及應用該關聯以鑑別對該HDAC抑制劑療法有產生抗性之風險之該癌症患者。亦提供一種鑑別對HDAC抑制劑療法產生陽性臨床反應之可能性增大之癌症患者的方法,其包含自該癌症患者獲得腫瘤樣品;偵測該樣品中睾丸特異性Y編碼樣蛋白質5(TSPYL5)表現之存在;定量該樣品中該TSPYL5之表現量,其中相對於該TSPYL5之既定表現臨限值,該TSPYL5之表現量低鑑別對該HDAC抑制劑療法產生陽性臨床反應之可能性增大之該癌症患者。亦提供相關方法及組合物。
